Biofrontera Inc. (BFRI): Cash & Equivalents
$6.39M
As of 2025-12-31
$4.66M
As of 2026-06-30
-28.1%
3-year compound annual growth
-4.6%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.39M | +8.2% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $5.91M | +339.7% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $1.34M | -92.2% | 2025-03-20, Balance as of period end |
| 2022-12-31 | $17.21M | -29.9% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $24.55M | +203.8% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $8.08M | n/a | 2022-04-11, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Biofrontera Inc. (BFRI) | 2025-12-31 | $6.39M | +8.2% |
| Wave Life Sciences, Inc. (WVE) | 2025-12-31 | $602.07M | +99.3% |
| Xilio Therapeutics, Inc. (XLO) | 2025-12-31 | $137.53M | +148.7% |
| Integrated Biopharma Inc (INBP) | 2026-06-30 | $4.47M | +23.7% |
| Cumberland Pharmaceuticals Inc (CPIX) | 2025-12-31 | $11.44M | -36.3% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $9.82M | 0.0% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $120.72M | -49.3% |
| Protagonist Therapeutics, Inc (PTGX) | 2025-12-31 | $128.39M | +32.0% |
| Lftd Partners Inc. (LIFD) | 2025-12-31 | $1.77M | -17.7% |
Compare BFRI, WVE, XLO, INBP side by side · Screen every company in Pharmaceutical Preparations ↗